Sight Sciences Reports Q1 2025 Financial Results

Sight Sciences ( (SGHT) ) has shared an announcement.

On May 8, 2025, Sight Sciences reported its financial results for the first quarter of 2025, showing a 9% decrease in total revenue compared to the previous year, primarily due to reduced revenue from its Surgical Glaucoma segment. The company reaffirmed its full-year revenue guidance for 2025, despite challenges posed by new Medicare LCDs affecting the MIGS market and tariff impacts on its products manufactured in China. Sight Sciences also launched OMNI Edge, a new product in its surgical system line, and announced improved adjusted operating expenses guidance for the year.

Spark’s Take on SGHT Stock

According to Spark, TipRanks’ AI Analyst, SGHT is a Neutral.

Sight Sciences faces significant financial challenges with declining revenues, persistent net losses, and negative cash flows, which weigh heavily on its stock score. Despite strong gross margins and liquidity, there are sustainability concerns. Technical analysis and valuation are neutral to slightly negative, reflecting the lack of strong market confidence. The earnings call and recent board appointment offer cautious optimism for future strategic initiatives. Overall, the stock score reflects the need for strategic improvements to boost financial performance and market confidence.

To see Spark’s full report on SGHT stock, click here.

More about Sight Sciences

Sight Sciences, Inc. is an eyecare technology company focused on developing and commercializing innovative interventional technologies aimed at transforming care and improving patients’ lives. The company operates primarily in the glaucoma and dry eye markets, providing products such as the OMNI Surgical System and TearCare.

Average Trading Volume: 242,178

Technical Sentiment Signal: Sell

Current Market Cap: $145.3M

For an in-depth examination of SGHT stock, go to TipRanks’ Stock Analysis page.